Zoetis Inc. shares dropped about 21.5% on May 7, 2026, after the company sharply cut its full-year 2026 revenue guidance to $9.68-$9.96 billion, down from a previously stated 3%-5% organic growth forecast. The revision came as internal data revealed weakening U.S. pet-care demand and increased competition, particularly a looming generic threat to its top dermatology drug. This sudden guidance cut surprised investors who were not aware of these internal challenges, leading to significant losses. Legal firm Levi & Korsinsky is investigating potential securities law violations related to possibly misleading statements made by Zoetis about its revenue outlook and market conditions.
Pomerantz LLP has filed a class action lawsuit against Zoetis Inc., alleging securities fraud and other unlawful practices following the company's announcement of a profit guidance cut for 2026. Zoetis reported flat net income of $601 million for Q1 ...
Pomerantz LLP has filed a class action lawsuit against Zoetis Inc., alleging securities fraud linked to the company's lowered 2026 profit guidance and a significant stock price drop. Zoetis reported flat net income for Q1 2026 and reduced its full-ye...
Zoetis, once a high-performing stock, has fallen about 70% from its peak in December 2021, mainly because its U.S. companion animal business saw an 11% organic decline in Q1 2026 after strong growth in 2021. The decline is linked to weaker U.S. consu...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by rising demand for rapid diagnostics, AI integration, and precision veterinary medicine, alongside i...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by increasing demand for rapid diagnostics, AI integration, robotic workflows, and a focus on companio...
